Chiesi and Protalix’s Therapy for Fabry Disease Receives Marketing Approval from EC
Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. have received marketing authorization from the European Commission (EC) for their drug,
Read moreChiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. have received marketing authorization from the European Commission (EC) for their drug,
Read moreThe Recombinant TEV Protease Protein His6 is a genetically optimised 28 kDa variation of the N1a protease from tobacco etch
Read moreEUCODIS Bioscience provides highly efficient custom recombinant protein services based on its vast experience in expression systems, downstream processing and
Read moreSanofi and GSK plan to make available to the Gavi lead COVAX Facility 200 million doses of their adjuvanted recombinant
Read moreEnzolytics, Inc, a drug development company with a focus on debilitating infectious diseases, announced on September 16, the execution of
Read moreSanofi and GSK are in preliminary talks with the European Commission (EC) on the supply of up to 300 million
Read more